Home Page / News and Events / Archived Releases / Press Release Details ...
April 1, 2008
BioTrove, Inc. Announces Filing of Registration Statement for Initial Public Offering
Woburn, MA, April 1, 2008 - BioTrove, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. Piper Jaffray & Co. and Lazard Capital Markets are acting as joint book-running managers and Robert W. Baird & Co. is acting as co-manager.
A copy of the written prospectus relating to these securities, when available, may be obtained by contacting either: Beth Davidge, , Attention: Prospectus Department, 800 Nicollet Mall, Minneapolis, MN 55402; or Lazard Capital Markets, Attention: Syndicate Department, 30 Rockefeller Plaza, New York, NY 10020 (212) 632-6717.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About BIOCIUS Life Sciences
BIOCIUS Life Sciences provides researchers faster answers to their lead discovery and in vitro ADME analyses through its RapidFire instrument and contract research services. RapidFire® enables the acceleration of drug discovery and pipeline decisions. With 13 of the top 15 largest biopharmaceutical companies based on global sales as clients, and partnerships with prestigious research and public health centers around the world, BIOCIUS’s products and services ensure that an industry committed to accuracy and speed can meet business goals.
RapidFire® Mass Spectrometry (RF-MS) feeds samples directly to the mass spectrometer at six to eight seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RF-MS is routinely used in many applications including the high-throughput screening of previously intractable drug targets and ADME assays.
BIOCIUS. Faster Answers.
RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,